Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+ CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC).

Howard I. Scher,Joseph Schonhoft,Ryon P. Graf,Adam Jendrisak,Ethan Barnett,Anuradha Jayaram,Eric Winquist,Mark Landers,Yipeng Wang,Alison L. Allan,Gerhardt Attard,Ryan Dittamore

Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+ CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC).

2019

Howard I. Scher
Joseph Schonhoft
Ryon P. Graf
Adam Jendrisak
Ethan Barnett
Anuradha Jayaram
Eric Winquist
Mark Landers
Yipeng Wang
Alison L. Allan
Gerhardt Attard
Ryan Dittamore

5075Background: Prediction of ARSi benefit in mCRPC is an unmet medical need. Recently, the Epic Sciences CTC based nl AR-V7 test validated as a predictive biomarker in two multi-center validation ...

Keywords:

Androgen receptor
Castration
Prostate cancer
Cancer research
Chromosome instability
Pathology
Biomarker (medicine)
Medicine
predictive biomarker
castration resistant
EPIC
Internal medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations